Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials

Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials

Background: Tapinarof cream 1% once daily (QD) demonstrated significant efficacy in patients down to age 2 years with atopic dermatitis (AD) in the ADORING 1 and 2 phase 3 trials. We report local tolerability outcomes.Methods: Patients received Tapinarof or vehicle cream QD for 8 weeks. Tolerability...

Full description

Saved in:
Bibliographic Details
Main Authors: Linda Stein Gold, James Del Rosso, Benjamin D. Ehst, Matthew J. Zirwas, Lawrence J. Green, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Anna M. Tallman
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Journal of Dermatological Treatment
Subjects:
Tapinarof cream 1% once daily
aryl hydrocarbon receptor agonist
atopic dermatitis
phase 3 trials
adults and children
local tolerability scale
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2024.2444489
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items